Last reviewed · How we verify

NCT03548636

Project MOVE: Increasing Physical Activity Among Breast Cancer Survivors

Completed NA Last updated 7 June 2018
What this trial tests

NA trial testing Single-Arm Feasibility Study in Cancer Prevention in 132 participants. Completed in 11 March 2017.

Timeline
17 September 2015
Primary endpoint
11 March 2017
11 March 2017

Quick facts

Lead sponsorUniversity of British Columbia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment132
Start date17 September 2015
Primary completion11 March 2017
Estimated completion11 March 2017

Drugs / interventions tested

Conditions studied

Sponsor

University of British Columbia

Who can join

18 and older, female only, with Cancer Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to implement and evaluate the feasibility of Project MOVE, a program aimed to increase physical activity among breast cancer survivors through microgrants and financial incentives.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
    Caperchione CM, Sabiston CM, Stolp S, Bottorff JL, et al · · 2019 · cited 11× · PMID 30917793 · DOI 10.1186/s12885-019-5470-2

Verify or expand the search:

Other trials of Single-Arm Feasibility Study

Trials testing the same drug.

Other recruiting trials for Cancer Prevention

Currently open trials in the same condition.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03548636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing